Mirati Therapeutics

Oncology

Mirati Therapeutics

Mirati Therapeutics (Nasdaq: MRTX) is focused on the development of novel therapeutics for the treatment of cancer.

Mirati Therapeutics (Nasdaq: MRTX) is focused on the development of novel therapeutics for the treatment of cancer.

Mirati Therapeutics was created from the drug discovery foundation of MethylGene and reshaped under the direction of a new leadership team with extensive experience in successful development and registration of targeted oncology drugs. Mirati is advancing three exciting oncology programs: MGCD265, mocetinostat and MGCD516 which were all discovered and developed internally.

The lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. It is also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma and MGCD516, a unique kinase inhibitor with a distinct target profile for the treatment of patients with non-small cell lung cancer and other solid tumors.


Latest News

Who's Who

Back to top